Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

By P. Schöffski, S. Chawla, R. Maki, A. Italiano, H. Gelderblom, E. Choy, G. Grignani, V. Camargo, S. Bauer, S. Rha and 8 more. The Lancet, 2016

681 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, methodology): “The median difference OS was 2 months [I, B], but a subgroup analysis showed that it reached 7 months in liposarcomas [42].”